Navigation Links
Regulus to Present at Future Leaders in the Biotech Industry Conference
Date:3/28/2013

LA JOLLA, Calif., March 28, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that Garry E. Menzel , Ph.D., Chief Operating Officer and Executive Vice President, Finance, will present a company overview at the 20th Annual Future Leaders in the Biotech Industry Conference on Friday, April 5, 2013 at 10:30 am EDT.  The conference is being held at the Millennium Broadway Hotel and Conference Center in New York City.

The presentation will be webcast at the time of the presentation and can be accessed on the Investor Relations page of the Company's website at www.regulusrx.com.  A replay of each webcast will be archived on the Company's website following the presentation date.

About Regulus

Regulus Therapeutics Inc. (NASDAQ: RGLS) is a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs. Regulus is leveraging a mature therapeutic platform based on technology that has been developed over 20 years. Regulus works with a broad network of academic collaborators and leverages the oligonucleotide drug discovery and development expertise of its founding companies, Alnylam Pharmaceuticals and Isis Pharmaceuticals. Regulus is advancing microRNA therapeutics toward clinical development in several areas, including oncology, fibrosis, hepatitis C and metabolic diseases. Regulus has formed strategic alliances with AstraZeneca, GlaxoSmithKline and Sanofi and a research collaboration with Biogen Idec.

For more information, please visit http://www.regulusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with Regulus' expectations regarding future therapeutic and commercial potential of Regulus' business plans, technologies and intellectual property related to microRNA therapeutics being discovered and developed by Regulus.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Regulus' current expectations and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  These and other risks concerning Regulus' programs are described in additional detail in Regulus' SEC filings.  All forward-looking statements contained in this press release speak only as of the date on which they were made. Regulus undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Regulus to Present at Cowen and Company 33rd Annual Healthcare Conference
2. Regulus Reports Fourth Quarter and Year-End 2012 Financial Results and Highlights
3. Regulus Announces Timing for Fourth Quarter and Year-End 2012 Financial Results Webcast and Conference Call
4. Regulus to Present at Two Upcoming Investor Conferences
5. Regulus Appoints Mark G. Foletta to its Board of Directors
6. Regulus Reports Third Quarter 2012 Financial Results and Recent Highlights
7. Regulus Announces Timing for Third Quarter 2012 Financial Results Webcast and Conference Call
8. Regulus Appoints Douglas E. Williams, Ph.D. to its Board of Directors
9. Regulus Announces $80.9 Million in Total Gross Proceeds from IPO and Other Recent Financial Transactions
10. Regulus Presents New Preclinical Data on miR-21 at Kidney Week 2012
11. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Mixed tocopherols market projected to grow at a CAGR of ... reach USD 5.27 billion by 2022, at a CAGR of ... as health and wellness trends, for instance, vitamin fortification in ... processing, packaging, and labeling of food & beverages. Additionally, the ... Asia-Pacific region also drives the market. ...
(Date:2/23/2017)... Mass. , February 23, 2017 - ...   ... Honoring Rare Disease Day Open to All at http://www.shire.com/RareCount   ... today announced the launch of ,Rare Count, in honor of Rare ... diseases, which equates to nearly one in 20 global citizens. It ...
(Date:2/22/2017)... -- Andre, DiMino, CEO of ADM Tronics Unlimited, Inc. (OTCQB: ... and products, commented on ADMT,s third quarter fiscal year ... the Company,s quarterly report on Form 10Q available at ... stated "During the quarter ended December 31, 2016 we ... portion of our engineering efforts into the development of ...
Breaking Medicine Technology:
(Date:2/22/2017)... Los Angeles, CA (PRWEB) , ... February 22, 2017 , ... ... medical detox treatment to the thousands of individuals who have recently fallen victim to ... accredited hospital in Orange County, California, where they are free from the shame, ...
(Date:2/22/2017)... ... February 22, 2017 , ... Giving ... fewer trips the emergency room, fewer hospital admissions, and better blood pressure and ... Care® (AJMC®) finds. The study can be found here . , The ...
(Date:2/22/2017)... , ... February 22, 2017 , ... Doctors on Liens ... of esteemed ophthalmologist, Dr. Steven H. Rauchman, practicing at North Valley Eye Medical ... accidents, product liability, premise liability and other personal injury cases. These injuries have ...
(Date:2/22/2017)... D.C. (PRWEB) , ... February 22, 2017 , ... ... being celebrated throughout the country today, as organizations, advocates, and individuals join together ... detection and treatment access to ultimately save lives. , “Today we mark a ...
(Date:2/22/2017)... Addison, TX (PRWEB) , ... February 22, 2017 ... ... announced the launch of ProGen™ PRP, the latest innovation in the delivery of ... orthopedics, wound care, aesthetics, cardiovascular and pain management, to accelerate tissue synthesis and ...
Breaking Medicine News(10 mins):